TRVN Stock Overview
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Trevena, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.43 |
52 Week High | US$3.28 |
52 Week Low | US$0.41 |
Beta | 1.12 |
1 Month Change | -22.47% |
3 Month Change | -38.31% |
1 Year Change | -43.82% |
3 Year Change | -99.02% |
5 Year Change | -98.91% |
Change since IPO | -99.73% |
Recent News & Updates
Recent updates
Trevena Q2 2022 Earnings Preview
Aug 10Trevena slides on $2M preferred stock offering
Jul 29Trevena (NASDAQ:TRVN) Will Have To Spend Its Cash Wisely
Jul 08Is Trevena (NASDAQ:TRVN) In A Good Position To Deliver On Growth Plans?
Mar 19Trevena Offers An Enticing Risk-Reward At These Prices
Dec 14Trevena: Remaining Patient After A Disappointing Q2 Earnings
Aug 17Trevena announces resumption of NIH-run trial for TRV734 in opioid use disorder
Jun 16Trevena's OLINVYK Provides One Of The Most Compelling Growth Profiles
May 10Trevena Investor Presentation - Slideshow
May 08Trevena (TRVN) Investor Presentation - Slideshow
Nov 16Trevena: Reaffirming A Buy On OLINVYK DEA Scheduling
Nov 09DEA classifies Trevena's oliceridine, distribution to start in November
Oct 30Shareholder Returns
TRVN | US Biotechs | US Market | |
---|---|---|---|
7D | -20.9% | 0.2% | 1.3% |
1Y | -43.8% | 10.2% | 29.8% |
Return vs Industry: TRVN underperformed the US Biotechs industry which returned 9.8% over the past year.
Return vs Market: TRVN underperformed the US Market which returned 30.4% over the past year.
Price Volatility
TRVN volatility | |
---|---|
TRVN Average Weekly Movement | 6.4% |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.8% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TRVN's share price has been volatile over the past 3 months.
Volatility Over Time: TRVN's weekly volatility has decreased from 57% to 6% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2007 | 35 | Carrie Bourdow | https://www.trevena.com |
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.
Trevena, Inc. Fundamentals Summary
TRVN fundamental statistics | |
---|---|
Market cap | US$8.43m |
Earnings (TTM) | -US$30.77m |
Revenue (TTM) | US$3.21m |
2.5x
P/S Ratio-0.3x
P/E RatioIs TRVN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
TRVN income statement (TTM) | |
---|---|
Revenue | US$3.21m |
Cost of Revenue | US$616.00k |
Gross Profit | US$2.59m |
Other Expenses | US$33.36m |
Earnings | -US$30.77m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.68 |
Gross Margin | 80.79% |
Net Profit Margin | -959.34% |
Debt/Equity Ratio | 835.2% |
How did TRVN perform over the long term?
See historical performance and comparison